Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: Are we there yet?

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 1, 2014, Pages 1-2

  Restrepo, Marcos I ^a   Anzueto, Antonio ^b   Murphy, Audie L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MACROLIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; EDITORIAL; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; PRIORITY JOURNAL;

AGE FACTORS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZITHROMYCIN; BRONCHODILATOR AGENTS; CARDIOVASCULAR SYSTEM; COMORBIDITY; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEARING LOSS; HUMANS; MACROLIDES; MUSCARINIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT;

EID: 84903845780     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201406-1014ED     Document Type: Editorial

References (17)

1. Vestbo J, Hurd SS, Agust́i AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2012;187: 347-365.
2. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370: 786-796.
3. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2013;11: CD009764.
4. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R; PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11: 10.
5. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365: 689-698.
6. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-Term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178: 1139-1147.
7. Pomares X, Montó n C, Espasa M, Casabon J, Monsó E, Gallego M. Long-Term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis 2011;6: 449-456.
8. He Z-Y, Ou L-M, Zhang J-Q, Bai J, Liu G-N, Li M-H, Deng J-M, MacNee W, Zhong X-N. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010;80: 445-452.
9. Hodge S, Reynolds PN. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology 2012; 17: 802-807.
10. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, Reynolds PN. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 139-148.
11. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013;1: 262-274.
12. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366: 1881-1890.
13. Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, Johnson CS, Alvarez CA, Frei CR, Good C, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014;311: 2199-2208.
14. Albert RK, Schuller JL; COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014;189: 1173-1180.
15. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC, Albert R, et al.; COPD Clinical Research Network. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014;189: 1503-1508.
16. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
17. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177: 19-26.